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Scientific objectives
A growing base of genetic testings is now available for
clinicians and its results could improve the quality of
care and its outcomes. In addition, these testings are
also helpful for predictive medicine and early detection
of diseases. Genetic testings could further personalize
the care processes based on the patient individual
genetic makeup. Genetic testing methods are diverse
and span from testing for known germline mutations in
the context of single-gene disorders, to full sequencing
of genes in tumor tissues looking for somatic variations
in cancer cells, and on to whole-exome sequencing in
cases of predictive medicine or unknown diagnosis. As a
consequence of that diversity and the constantly grow-
ing number of techniques yielding new result formats
less familiar to clinicians, existing report formats
attempt to contain rather detailed descriptions of the
tests performed, but that approach makes it hard to
understand the interpretations of the testing results and
given recommendations. Genetic testing reports should
be both human readable to its users, and at the same
time also be processable to computerized algorithms
computing the interpretation of the genetic testing
results. Thus, it is equally important to standardize the
way genetic testing interpretations are represented [1] as
an inherent part of the report structure.
Technological approaches
Given the above considerations, it is important to
streamline the utilization of genetic testing reports by
standardizing its format. The GTR (Genetic Testing
Report) standard was published in February 2013 [2]. It
is derived from the CDA (Clinical Document Architec-
ture) standard [3] and further specializes the CDA clini-
cal statement model in order to represent genotype-
phenotype associations. The GTR Clinical Genomic
Statement suggests a semantic representation (see figure
1) of genotype-phenotype associations, in a way that
decision support applications can run reasoning algo-
rithms without basing the inference on implicit associa-
tions where prior knowledge is needed [1].
Results
The GTR standard can facilitate true semantic intero-
perability among all personalized healthcare stake-
holders, e.g., genetic labs, EHR systems, patients, clinical
trials and research, public health agencies, etc. The GTR
is flexible enough to be further constrained for more
specific usages, e.g., requirements in different countries,
research vs. clinical environments, professional societies
recommended-formats, specific omics technologies /
methodologies, or special use cases such as tissue typing
or whole-exome sequencing report.
Outlook and expert recommendations
The GTR has been developed using MDHT (Model-Dri-
ven Health Tool) - an open source effort that is used
worldwide to develop specialized standards based on
UML models of common and generic standards like the
CDA [4]. The MDHT also enables automatic code gen-
eration of software components that impalement the
GTR and thus could facilitate the streamlining of
genetic testing report utilization, as it is easier to
develop or upgrade healthcare information systems to
support the GTR.
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Figure 1 The Clinical Genomics Statement: Towards standardized language bridging the genomic and clinical worlds.
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